MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case ...

TORONTO and HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the ...

Step-by-step guide to mastering Meta Ray-Ban Smart Glasses setup and usage for a seamless and hands-free connected experience. Ray-Ban - Official site Meta Ray-Ban Smart Glasses blend style and ...

Motion smoothing has a bad reputation among most cinephiles, as well as many home theater enthusiasts and content creators. Also known as motion or video interpolation, motion smoothing is available ...

When graphic design platform-provider Canva bought the Affinity image-editing and publishing apps early last year, we had some major questions about how the companies’ priorities and products would ...

The Cyprus Institute of Neurology and Genetics (CING) has acquired an advanced spatial transcriptomics platform for biological tissue analysis, according to an announcement released this week. The ...

KENILWORTH (NJ) (dpa-AFX) - IO Biotech (IOBT), a clinical-stage biopharmaceutical company focused on cancer vaccines, Monday reported positive phase 3 results for Cylembio, in combination with Merck & ...

(RTTNews) - IO Biotech (IOBT), a clinical-stage biopharmaceutical company focused on cancer vaccines, Monday reported positive phase 3 results for Cylembio, in combination with Merck & Co Inc.'s (MRK) ...

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression ...